Epredia 推出激光盒式打印机，旨在提高样品跟踪和实验室效率

。

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523),  and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScanTM, a product under development as a medical device designed to support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, to support distribution of this new device to surgeons after it is on the market.

Skin cancer is the most common group of cancers diagnosed worldwide , and it is estimated that one in five Americans will develop skin cancer in their lifetime . Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year . Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer. 

MarginScan™ is being designed to address this challenge by supporting Mohs surgery procedures for skin cancer treatment. Mohs Micrographic Surgery (MMS) is an operative method used to detect the presence or absence of a tumor in the margins of a surgical excision. In an MMS procedure, cancer tissue is excised in stages, then flash-frozen and assessed histologically in an onsite lab until clean margins are obtained. Previously, MMS was the only modality for skin cancer treatment that involved comprehensive margin assessment during a procedure. MarginScan™ is being designed to use an electrical assessment to confirm cancer-free margins without the intraoperative histological assessment. This has the potential to allow for faster excisions that spare more healthy tissue, leading to improved outcomes for both patients and clinicians.

With this agreement, Epredia plans to serve as the primary distribution partner of MarginScan™ and have exclusive distribution rights in the United States. Along with distribution, Epredia plans to be responsible for all marketing and commercial activities related to the launch and sale of MarginScan™. After product launch, Epredia will work closely with Avantik to market and sell the new device to Mohs surgeons.

Under these planned arrangements, after launch, MarginScan™ will be the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow, including slide scanners and printers, cryostats, tissue processors, and consumables such as slides and reagents. In addition to offering MarginScan™, Epredia also has plans to provide consumable products that are used with the device, such as the MarginScan™ electrode and proprietary electrolytic gel used during excisions. 

The two companies anticipate a 2025 U.S. launch for MarginScan™. The planned distribution agreement builds on a previous agreement between NovaScan and PHC Corporation, another subsidiary of PHC Holdings Corporation that is focused on the development and manufacturing of innovative medical testing devices. PHC Holdings Corporation is referred to collectively with its subsidiaries as PHC Group.  

Steven Lynum, President of Epredia, said, “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions. Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”

Craig Davis, CEO of NovaScan, remarked, “NovaScan is thrilled to be making plans with Epredia to bring MarginScan™ to clinical healthcare providers in the U.S. We will be proud for MarginScan™ to join Epredia’s portfolio of market-leading cancer diagnostics products in the future. We believe that MarginScan™ will play an important role in skin cancer detection and treatment”

Mark Zacur, CEO of Avantik, added, “Our team is continually sourcing the best solutions to expand our portfolio of solutions supporting Mohs clinics with their critical work. We are honored that Epredia selected Avantik as their partner for this planned initiative to bring this breakthrough device to our network of providers and their patients when it is launched.”

---

关于 Epredia

Epredia是解剖病理学领域的全球领导者，为癌症精准诊断和组织诊断提供全面的解决方案。Epredia拥有Erie Scientific、Menzel-Gläser、Microm、Shandon和Richard-Allan Scientific等主要品牌，产品组合包括显微镜载玻片、仪器和耗材。Epredia 是 PHC Holdings 于 2019 年收购赛默飞世尔科技公司解剖病理学业务后成立的。Epredia在美国、英国、德国、瑞士和中国的主要基地开展业务，共有约1200名员工。Epredia 致力于通过提高全球患者的癌症诊断水平来实现改善生活的使命。欲了解有关 Epredia 及其产品的更多信息，请访问www.epredia.com。

中国医学科学院肿瘤医院

关于PHC控股公司（PHC集团）

PHC Holdings Corporation（东京证券交易所股票代码：6523）是一家全球性医疗保健公司，其使命是通过具有积极影响并能改善人们生活的医疗保健解决方案为社会健康做出贡献。其子公司（统称为 PHC 集团）包括 PHC Corporation、Epredia、Ascensia Diabetes Care、LSI Medience Corporation、Mediford 和 Wemex。这些公司共同开发、生产、销售和服务糖尿病管理、医疗保健解决方案、生命科学和诊断解决方案。PHC 集团 2022 财年的合并净销售额为 3,564 亿日元，产品和服务遍布全球 125 个国家。

欲了解更多信息，请联系：

Julia Cottrill
PHC 集团企业传讯部
电子邮件：julia.cottrill@phchd.com